findmyKOL

Robert Weinreb, MD

Enriched profile

Chair and Distinguished Professor, Viterbi Family Department of Ophthalmology; Director, Shiley Eye Institute; Director, Hamilton Glaucoma Center; Morris Gleich, MD Chair of Glaucoma; Distinguished Professor of Bioengineering · University of California San Diego

ORCIDNPI
Region🇺🇸 San Diego, CA · West · United StatesSpecialtyOphthalmologyFocusGlaucoma and retinal disorders+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1985–2025

Robert Weinreb is Chair and Distinguished Professor, Viterbi Family Department of Ophthalmology; Director, Shiley Eye Institute; Director, Hamilton Glaucoma Center; Morris Gleich, MD Chair of Glaucoma; Distinguished Professor of Bioengineering at University of California San Diego. OpenAlex indexes 1,579 publications with 71,138 citations (h-index 128); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Ophthalmology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Robert Weinreb, MD, is Chair and Distinguished Professor, Viterbi Family Department of Ophthalmology at University of California San Diego (Shiley Eye Institute / Viterbi Family Department of Ophthalmology). The public record shows 1,579 publications with 71,138 citations (h-index 128), centered on Glaucoma and retinal disorders, Retinal Diseases and Treatments, Corneal surgery and disorders. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 11 companies, 9 NIH-funded awards (1985–2025).

  • Most recent indexed publication: 2026 · The British journal of ophthalmology
  • Top research focus: Glaucoma and retinal disorders
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma5 trialsComa5 trialsHypertension1 trialOcular Hypertension1 trialMyopia1 trialMacular Degeneration (AMD)

Research focus

OpenAlex concept fingerprint
Glaucoma and retinal disordersRetinal Diseases and TreatmentsCorneal surgery and disordersRetinal Imaging and AnalysisOphthalmology and Visual Impairment Studies

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trialsIndustry payments14PublicationsRhopressageneric · NetarsudilClinical trialsIndustry payments5PublicationsRocklatangeneric · Latanoprost / netarsudilClinical trialsIndustry payments5Publications

Works with

trial sponsors and companies reporting payments
Topcon CorporationClinical trials1Industry payments2Topcon Healthcare, Inc.Clinical trialsIndustry payments102Alcon Vision LLCClinical trialsIndustry payments40

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,579publications

Distinct works indexed by OpenAlex, matched via ORCID; 44 in PubMed.

71,138citations

Total citations across indexed works.

128h-index

Hirsch index (OpenAlex). i10-index 897.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
9NIH grants · 1985–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    90.8%
    Prostaglandin Analog50.2%
    Latanoprost86%Lumigan8%Travoprost3%Tafluprost2%Travatan Z1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor26.8%
    Dorzolamide-Timolol75%Dorzolamide Hcl14%Brinzolamide6%Simbrinza5%
    Part D<11 patients
  • Cardiovascular

    7.2%
    Beta blocker7.2%
    Timolol Maleate100%
    Part D87 patients
  • Cancer & immunology

    2%
    Nucleoside Metabolic Inhibitor2%
    Fluorouracil100%
    Part B, office-administered21 patients
Where care is delivered (Part B)4.1% facility · 95.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

9 NIH research awards on record, funded 19852025 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

1 congress contribution (2023) across ADA per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Linda M. Zangwill609Felipe A. Medeiros316Christopher Bowd292

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-weinreb-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Robert-Weinreb

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/UCSDShileyEye/photos/sei-is-proud-to-recognize-chair-director-robert-n-weinreb-md-for-being-ranked-nu/1295289021808262

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Facebook

    facebook.com/UCSDShileyEye/posts/just-published-robert-n-weinreb-md-led-sei-clinician-scientists-in-collaboration/1257324728938025

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • LinkedIn

    linkedin.com/posts/eyenovia_robert-weinreb-md-is-a-valued-member-or-our-activity-7052646316916584449-qppJ

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Co-Editor

    Journal of Glaucoma

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →research.com
  • Chief Editor

    International Glaucoma Review

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →research.com
  • Member

    Editorial Board, Investigative Ophthalmology and Visual Science

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →research.com
7 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
7 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Member

    Science Advisory Board, Spinogenix

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globenewswire.com
  • Chair

    Scientific Advisory Board, Amydis Inc.

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amydis.com

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.